Unpredictable rotational responses to L-dopa in the rat model of Parkinson's disease: The role of L-dopa pharmacokinetics and striatal dopamine depletion

Basic and Clinical Pharmacology and Toxicology

Volumn 110, Issue 2, 2012, Pages 162-170

  Kääriäinen, Tiina M ^a   Käenmäki, Mikko ^b   Forsberg, Markus M ^a   Oinas, Niko ^a   Tammimäki, Anne ^b   Männistö, Pekka T ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; LEVODOPA; LEVODOPA METHYL ESTER; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE DEPLETION; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BLOOD LEVEL; DRUG EFFICACY; MALE; MEDIAL FOREBRAIN BUNDLE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; INTRAPERITONEAL DRUG ADMINISTRATION; MOTOR ACTIVITY; ORAL DRUG ADMINISTRATION; ROTATION; WISTAR RAT;

RATTUS;

ADMINISTRATION, ORAL; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAPERITONEAL; LEVODOPA; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, WISTAR; ROTATION;

EID: 84855955204     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00782.x     Document Type: Article

References (40)

1. Poewe W. Treatments for Parkinson disease - past achievements and current clinical needs. Neurology 2009;72:S65-73.
2. Jankovic J. Levodopa strengths and weaknesses. Neurology 2002;58:S19-32.
3. Blandini F, Armentero MT, Martignoni E. The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord 2008;14(Suppl 2):S124-9.
4. Carey RJ. Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance. Brain Res 1991;568:205-14.
5. Duty S, Brotchie JM. Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression. Exp Neurol 1997;144:423-32.
6. Lindgren HS, Rylander D, Ohlin KE, Lundblad M, Cenci MA. The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav Brain Res 2007;177:150-9.
7. Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 1994;662:69-74.
8. Männistö PT, Ulmanen I, Lundström K, Taskinen J, Tenhunen J, Tilgmann C et al. Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 1992;39:291-350.
9. Contin M, Martinelli P. Pharmacokinetics of levodopa. J Neurol 2010;257:S253-61.
10. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984;7:35-49.
11. Müller T, Erdmann C, Bremen D, Schmidt WE, Muhlack S, Woitalla D et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol 2006;29:61-7.
12. Haefeli WE. Drug-drug interactions with levodopa modulating treatment responses in Parkinson's disease. J Neurol 2007; 254:IV29-36.
13. Ogawa N. Factors affecting levodopa effects in Parkinson's disease. Acta Med Okayama 2000;54:95-101.
14. LeWitt PA. The pharmacology of levodopa in the treatment of Parkinson's disease: an update. In: Calne DB (ed.). Drugs for the Treatment of Parkinson's disease. Springer-Verlag, Berlin, 1989;325-84.
15. Bredberg E, Lennernäs H, Paalzow L. Pharmacokinetics of levodopa and carbidopa in rats following different routes of administration. Pharm Res 1994;11:549-55.
16. Cooper DR, Marrel C, van de Waterbeemd H, Testa B, Jenner P, Marsden CD. L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease. J Pharm Pharmacol 1987;39:627-35.
17. 3-ligands on the levodopa-induced turning behavior of hemiparkinsonian rats. Parkinsonism Relat Disord 2000;6:159-64.
18. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Academic Press, New York, 1986.
19. Käenmäki M, Tammimäki A, Garcia-Horsman JA, Myöhänen T, Schendzielorz N, Karayiorgou M et al. Importance of membrane-bound catechol-O-methyltransferase in L-DOPA metabolism: a pharmacokinetic study in two types of Comt gene modified mice. Br J Pharmacol 2009;158:1884-94.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
21. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
22. U.S. Department of Health and Human Services. Guidance for Industry, Bioanalytical Method Validation, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), 2001., April 2011.
23. Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 2008;23(Suppl 3):S580-4.
24. Nadjar A, Gerfen CR, Bezard E. Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? Prog Neurobiol 2009;87:1-9.
25. Pinheiro-Carrera M, Tomaz C, Huston JP, Dai H, Carey RJ. 'Priming' enhances the relationship of striatal L-dopa concentration to behavior. Neuroreport 1994;5:1665-9.
26. Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, Cenci MA. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem 2006;96:1718-27.
27. Lane EL, Cheetham SC, Jenner P. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? Exp Neurol 2006;197:284-90.
28. Lane EL, Daly CS, Smith GA, Dunnett SB. Context-driven changes in l-DOPA-induced behaviours in the 6-OHDA lesioned rat. Neurobiol Dis 2011;42:99-107.
29. Carta AR, Frau L, Pontis S, Pinna A, Morelli M. Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence. Parkinsonism Relat Disord 2008;14(Suppl 2):S165-8.
30. Henry B, Crossman AR, Brotchie JM. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 1998;151:334-42.
31. Stocchi F, Barbato L, Bramante L, Nordera G, Vacca L, Ruggieri S. Fluctuating parkinsonism: a pilot study of single afternoon dose of levodopa methyl ester. J Neurol 1996;243:377-80.
32. Cooper DR, Marrel C, Testa B, van de Waterbeemd H, Quinn N, Jenner P et al. L-Dopa methyl ester - a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease. Clin Neuropharmacol 1984;7:89-98.
33. Gancher ST, Nutt JG, Woodward WR. Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients. Neurology 1987;37:940-4.
34. Carvey PM, Zhao CH, Hendey B, Lum H, Trachtenberg J, Desai BS et al. 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. Eur J Neurosci 2005;22:1158-68.
35. Westin JE, Lindgren HS, Gardi J, Nyengaard JR, Brundin P, Mohapel P et al. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3, 4-dihydroxyphenyl-L-alanine-induced dyskinesia. J Neurosci 2006;26:9448-61.
36. Sarre S, Herregodts P, Deleu D, Devrieze A, De Klippel N, Ebinger G et al. Biotransformation of L-dopa in striatum and substantia nigra of rats with a unilateral, nigrostriatal lesion: a microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 1992;346:277-85.
37. Abercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 1990;525:36-44.
38. Kostrzewa RM, Nowak P, Kostrzewa JP, Kostrzewa RA, Brus R. Peculiarities of L-DOPA treatment of Parkinson's disease. Amino Acids 2005;28:157-64.
39. Lopez A, Munoz A, Guerra MJ, Labandeira-Garcia JL. Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum. Neuroscience 2001;103:639-51.
40. Hefti F, Melamed E, Sahakian BJ, Wurtman RJ. Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA. Pharmacol Biochem Behav 1980;12:185-8.